These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16713660)

  • 1. GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
    Gao J; Huang S; Li M; Luo R; Wang X; Takashima A
    Vaccine; 2006 Jun; 24(25):5265-8. PubMed ID: 16713660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.
    Chatterjee SK; Qin H; Manna S; Tripathi PK
    Anticancer Res; 1999; 19(4B):2869-73. PubMed ID: 10652566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
    Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
    J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigens and cytokine genes in antitumor vaccines: the importance of the temporal delivery sequence in antitumor signals.
    Herrero MJ; Botella R; Dasí F; Algás R; Sánchez M; Aliño SF
    Ann N Y Acad Sci; 2006 Dec; 1091():412-24. PubMed ID: 17341632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.
    Prell RA; Li B; Lin JM; VanRoey M; Jooss K
    Cancer Res; 2005 Mar; 65(6):2449-56. PubMed ID: 15781661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.
    Miguel A; Herrero MJ; Sendra L; Botella R; Algás R; Sánchez M; Aliño SF
    Cancer Gene Ther; 2013 Oct; 20(10):576-81. PubMed ID: 23969885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
    Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB
    Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
    Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
    Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically engineered tumor cell vaccine in a head and neck cancer model.
    Couch M; Saunders JK; O'Malley BW; Pardoll D; Jaffee E
    Laryngoscope; 2003 Mar; 113(3):552-6. PubMed ID: 12616213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
    Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
    J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.
    Ozbek S; Peters M; Breuhahn K; Mann A; Blessing M; Fischer M; Schirmacher P; Mackiewicz A; Rose-John S
    Oncogene; 2001 Feb; 20(8):972-9. PubMed ID: 11314032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.
    Yin W; He Q; Hu Z; Chen Z; Qifeng M; Zhichun S; Zhihui Q; Xiaoxia N; Li J; Gao J
    Vaccine; 2010 Jul; 28(31):4937-44. PubMed ID: 20653081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.
    Moret-Tatay I; Díaz J; Marco FM; Crespo A; Aliño SF
    Cancer Gene Ther; 2003 Dec; 10(12):887-97. PubMed ID: 14712315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
    Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M
    Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.